Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Abbvie Biotechnology Ltd.
EIR
•Abbvie Biotechnology Ltd.•January 13, 2017

Abbvie Biotechnology Ltd. – FDA EIR, Jan 13, 2017

Record Details

An FDA pre-approval inspection was conducted at AbbVie Biotechnology Ltd.'s facility in Barceloneta, PR, from January 9-13, 2017. The inspection focused on the manufacturing of Vedolizumab drug substance to support a prior-approval supplement, operating under FDA Compliance Programs and ICH Q7 Good Manufacturing Practice guidelines. The inspection resulted in an FDA Form 483 detailing four significant observations. Key issues included inadequate investigations into deviations, specifically regarding recurring low-level microbial contamination (Nectria mauritiicola), where a previous investigation was closed without identifying a root cause or implementing effective corrective actions. The Quality Unit also failed to ensure complete and accurate production batch records; an out-of-specification result for a critical optical density test was not properly investigated, leading to the release of affected drug substance batches, and the firm continued using the impacted component. Furthermore, laboratory procedures for investigating invalid assays were deemed insufficient, and the Vedolizumab drug substance batch record lacked specific filtration process details as recommended by the filter vendor. AbbVie's management acknowledged these observations and committed to submitting a comprehensive written response to the agency outlining their proposed corrective and preventive actions.

Company
Abbvie Biotechnology Ltd.
Inspection date
January 13, 2017
Product type
biologics
People
  • Ramesh Potla
  • Steven E. Bowen (Principal Consultant- CMC Biologics, Former FDA regulator with expertise in CMC and GMP for Biologics)
  • David L. Thompson (recipient)
  • Jose A. Marrero (company_representative)
  • Thuy T. Nguyen ( Investigator, Consumer Safety Officer)
View Company Profile

ID · b46b0168-1899-4d02-b119-b2104039df67

Violation Codes2
21 CFR 820.19821 CFR 820.50

Full citation text and observation details available on the Dashboard.

Other documents for Abbvie Biotechnology Ltd.
  • 483 - 2026-06-10June 10, 2026
  • 483 - 2023-10-30October 30, 2023
  • EIR - 2019-03-25March 25, 2019
  • 483 - 2019-03-25March 25, 2019
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Abbvie Biotechnology Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.